Prime Medicine, Inc. Increase Decrease In Operating Lease Liability
Prime Medicine, Inc. (PRME) reported Increase Decrease In Operating Lease Liability of -$3.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Prime Medicine, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$2.03M.
- Prime Medicine, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.92M.
- Prime Medicine, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.71M.
- Prime Medicine, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.60M.
- Prime Medicine, Inc. increase decrease in operating lease liability for fiscal 2025 was -$5.36M.
- Prime Medicine, Inc. increase decrease in operating lease liability for fiscal 2024 was -$6.46M.
- Prime Medicine, Inc. increase decrease in operating lease liability for fiscal 2023 was -$12.30M.
- Prime Medicine, Inc. increase decrease in operating lease liability for fiscal 2022 was -$10.25M.
| Period end | Increase Decrease In Operating Lease Liability 1 month | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.95M 10-Q · filed 2026-08-06 | -$5.66M derived: sum of 3 quarters · filed 2026-08-06 | -$7.26M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$1.92M 10-Q · filed 2026-05-07 | -$3.62M derived: sum of 2 quarters · filed 2026-05-07 | -$5.22M derived: sum of 3 quarters · filed 2026-05-07 | -$6.64M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$3.31M derived: sum of 2 quarters · filed 2026-03-03 | -$4.72M derived: sum of 3 quarters · filed 2026-08-06 | -$5.36M 10-K · filed 2026-03-03 | |
| 2025-09-30 | -$1.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$3.02M derived: sum of 2 quarters · filed 2026-08-06 | -$3.65M 10-Q · filed 2025-11-07 | -$4.11M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.05M 10-Q · filed 2026-08-06 | -$2.51M derived: sum of 3 quarters · filed 2026-08-06 | -$2.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$638.00K 10-Q · filed 2026-05-07 | -$1.09M derived: sum of 2 quarters · filed 2026-05-07 | -$1.43M derived: sum of 3 quarters · filed 2026-05-07 | -$3.64M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$454.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$789.00K derived: sum of 2 quarters · filed 2026-03-03 | -$3.00M derived: sum of 3 quarters · filed 2026-03-03 | -$6.46M 10-K · filed 2026-03-03 | |
| 2024-09-30 | -$335.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$2.54M derived: sum of 2 quarters · filed 2025-11-07 | -$6.01M 10-Q · filed 2025-11-07 | -$9.43M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | -$2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$5.67M 10-Q · filed 2025-08-07 | -$9.10M derived: sum of 3 quarters · filed 2025-08-07 | -$11.40M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$3.46M 10-Q · filed 2025-05-08 | -$6.89M derived: sum of 2 quarters · filed 2025-05-08 | -$9.19M derived: sum of 3 quarters · filed 2025-05-08 | -$12.98M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$5.73M derived: sum of 2 quarters · filed 2025-02-28 | -$9.52M derived: sum of 3 quarters · filed 2025-02-28 | -$12.30M 10-K · filed 2025-02-28 | |
| 2023-11-30 | $6.10M 10-K · filed 2024-03-01 | ||||
| 2023-09-30 | -$2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$6.09M derived: sum of 2 quarters · filed 2024-11-12 | -$8.87M 10-Q · filed 2024-11-12 | -$11.56M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.57M 10-Q · filed 2024-08-08 | -$9.26M derived: sum of 3 quarters · filed 2024-08-08 | -$12.56M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$2.78M 10-Q · filed 2024-05-10 | -$5.47M derived: sum of 2 quarters · filed 2024-05-10 | -$8.77M derived: sum of 3 quarters · filed 2024-05-10 | -$10.72M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$5.99M derived: sum of 2 quarters · filed 2024-03-01 | -$7.94M derived: sum of 3 quarters · filed 2024-03-01 | -$10.25M 10-K · filed 2024-03-01 | |
| 2022-09-30 | -$3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$5.25M derived: sum of 2 quarters · filed 2023-11-03 | -$7.56M 10-Q · filed 2023-11-03 | -$9.14M derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$4.26M 10-Q · filed 2023-08-07 | -$5.84M derived: sum of 3 quarters · filed 2023-08-07 | ||
| 2022-03-31 | -$2.31M 10-Q · filed 2023-05-11 | -$3.89M derived: sum of 2 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$4.33M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | -$2.74M 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |